Overview

BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Progression-free rate after 16 weeks of BIBW 2992 administration in association with letrozole
Phase:
Phase 2
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Afatinib
Letrozole